Regulus Therapeutics Inc (RGLS) - Total Assets
Based on the latest financial reports, Regulus Therapeutics Inc (RGLS) holds total assets worth $74.83 Million USD as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Regulus Therapeutics Inc debt service capacity to assess how comfortably operating cash covers total debt obligations.
Regulus Therapeutics Inc - Total Assets Trend (2010–2024)
This chart illustrates how Regulus Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See Regulus Therapeutics Inc (RGLS) net assets for net asset value and shareholders' equity analysis.
Regulus Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Regulus Therapeutics Inc's total assets of $74.83 Million consist of 97.8% current assets and 2.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 45.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $25.00K | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2010–2024)
This chart illustrates how Regulus Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Regulus Therapeutics Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Regulus Therapeutics Inc's current assets represent 97.8% of total assets in 2024, an increase from 92.4% in 2010.
- Cash Position: Cash and equivalents constituted 45.8% of total assets in 2024, up from 35.6% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2010.
- Asset Diversification: The largest asset category is intangible assets at 0.0% of total assets.
Regulus Therapeutics Inc Competitors by Total Assets
Key competitors of Regulus Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Regulus Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 16.31 | 17.32 | 1.36 |
| Quick Ratio | 16.31 | 16.79 | 1.18 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $67.30 Million | $92.75 Million | $7.61 Million |
Regulus Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Regulus Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.19 |
| Latest Market Cap to Assets Ratio | 6.71 |
| Asset Growth Rate (YoY) | 173.8% |
| Total Assets | $84.18 Million |
| Market Capitalization | $564.95 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Regulus Therapeutics Inc's assets at a significant premium (6.71x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Regulus Therapeutics Inc's assets grew by 173.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Regulus Therapeutics Inc (2010–2024)
The table below shows the annual total assets of Regulus Therapeutics Inc from 2010 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $84.18 Million | +173.76% |
| 2023-12-31 | $30.75 Million | -34.18% |
| 2022-12-31 | $46.72 Million | -31.76% |
| 2021-12-31 | $68.45 Million | +82.04% |
| 2020-12-31 | $37.60 Million | -10.64% |
| 2019-12-31 | $42.08 Million | +50.68% |
| 2018-12-31 | $27.93 Million | -64.11% |
| 2017-12-31 | $77.81 Million | -22.70% |
| 2016-12-31 | $100.66 Million | -28.65% |
| 2015-12-31 | $141.08 Million | -17.73% |
| 2014-12-31 | $171.48 Million | +39.34% |
| 2013-12-31 | $123.06 Million | +18.88% |
| 2012-12-31 | $103.52 Million | +141.41% |
| 2011-12-31 | $42.88 Million | -28.18% |
| 2010-12-31 | $59.70 Million | -- |
About Regulus Therapeutics Inc
Regulus Therapeutics Inc. engages in the development of drugs designed to inhibit dysregulated microRNA targets for the benefit of patients with genetically based orphan diseases. The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target o… Read more